CB-1 receptor modulator formulations
View Patent ↗Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabiniod inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.
1. A pharmaceutical formulation comprising a solid dispersion made by hot-melt extrusion comprising a cannabinoid receptor inverse agonist having formula I:
and a concentration-enhancing polymer selected from the group consisting of polyvinylpyrrolidinone, and polyvinylpyrrolidinone-polyvinylacetate copolymers, wherein the concentration-enhancing polymer comprises 80%-95% of the solid dispersion by weight.
2. The pharmaceutical formulation of claim 1 , wherein the solid dispersion further comprises a surfactant.
3. The solid dispersion of claim 2 , wherein the surfactant is selected from the group consisting of anionic surfactants and nonionic surfactants.
4. The solid dispersion of claim 2 , wherein the surfactant is selected from the group consisting of sodium dodecyl sulphate, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oils, polyoxyethylene hydrogenated castor oils, vitamin E TPGS; and mixtures thereof.
5. The solid dispersion of claim 1 , wherein the cannabinoid receptor inverse agonist comprises 5%, 10% or 20% of the solid dispersion by weight.
6. The pharmaceutical formulation of claim 1 further comprising an additional therapeutic agent.
7. The pharmaceutical formulation of claim 6 , wherein the additional therapeutic agent is a dipeptidyl peptidase-IV inhibitor.
8. The pharmaceutical formulation of claim 7 , wherein the dipeptidyl peptidase-IV inhibitor is sitagliptin or a pharmaceutically acceptable salt thereof.
9. The pharmaceutical formulation of claim 7 , wherein the dipeptidyl peptidase-IV inhibitor is sitagliptin dihydrogenphosphate.
10. The pharmaceutical formulation of claim 1 , wherein the dosage form contains 0.5 mg to 6 mg of the cannabinoid receptor inverse agonist.
11. The pharmaceutical formulation of claim 1 , wherein the dosage form contains 25 mg to 200 mg of the dipeptidyl peptidase-IV inhibitor.
12. The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation is a tablet or caplet.
13. A method of treating obesity comprising administering to a patient in need thereof a pharmaceutical formulation of claim 1 .
14. The method of claim 13 , wherein the pharmaceutical formulation further comprises a surfactant.
15. The method of claim 13 , wherein the pharmaceutical formulation is in the form of a tablet.